Sesamin inhibits lipopolysaccharide-induced proliferation and invasion through the p38-MAPK and NF-κB signaling pathways in prostate cancer cells

Oncology Reports

Volumn 33, Issue 6, 2015, Pages 3117-3123

  Xu, Peiyuan ^a   Cai, Fei ^a   Liu, Xiaofei ^a   Guo, Lele ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Invasion; LPS; Proliferation; Prostate cancer; Sesamin

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CYCLIN D1; CYCLOOXYGENASE 2; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BCL 2; SESAMIN; SMALL INTERFERING RNA; SYNAPTOPHYSIN; TRANSFORMING GROWTH FACTOR ALPHA; VASCULOTROPIN; 1,3 DIOXOLANE DERIVATIVE; CYTOKINE; IMIDAZOLE DERIVATIVE; LIGNAN; PYRIDINE DERIVATIVE; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL LINE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOSE RESPONSE; DOWN REGULATION; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PC3 CELL LINE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SUPERNATANT; TUMOR INVASION; BIOSYNTHESIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; PHOSPHORYLATION; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINES; DIOXOLES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; LIGNANS; LIPOPOLYSACCHARIDES; MALE; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PYRIDINES; SIGNAL TRANSDUCTION;

EID: 84928898588     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3888     Document Type: Article

References (39)

1. Lin SS, Clarke CA, Prehn AW, Glaser SL, West DW and O'Malley CD: Survival differences among Asian subpopulations in the United States after prostate, colorectal, breast, and cervical carcinomas. Cancer 94: 1175-1182, 2002.
2. Hsing AW, Tsao L and Devesa SS: International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 85: 60-67, 2000.
3. Hsing AW and Devesa SS: Trends and patterns of prostate cancer: what do they suggest? Epidemiol Rev 23: 3-13, 2001.
4. Sonn GA, Aronson W and Litwin MS: Impact of diet on prostate cancer: a review. Prostate Cancer Prostatic Dis 8: 304-310, 2005.
5. Schetter AJ, Heegaard NH and Harris CC: Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis 31: 37-49, 2010.
6. Coussens LM and Werb Z: Inflammation and cancer. Nature 420: 860-867, 2002.
7. Mantovani A: Cancer: inflammation by remote control. Nature 435: 752-753, 2005.
8. Hsu RY, Chan CH, Spicer JD, Rousseau MC, Giannias B, Rousseau S and Ferri LE: LPS-induced TLR4 signaling in human colorectal cancer cells increases beta1 integrin-mediated cell adhesion and liver metastasis. Cancer Res 71: 1989-1998, 2011.
9. Li J, Chong T, Wang Z, Chen H, Li H, Cao J, Zhang P and Li H: A novel anti-cancer effect of resveratrol: reversal of epithelial mesenchymal transition in prostate cancer cells. Mol Med Rep 10: 1717-1724, 2014.
10. Im HJ, Park NH, Kwon YJ, Shin S, Kim D and Chun YJ: Bacterial lipopolysaccharides induce steroid sulfatase expression and cell migration through IL-6 pathway in human prostate cancer cells. Biomol Ther (Seoul) 20: 556-561, 2012.
11. Michalaki V, Syrigos K, Charles P and Waxman J: Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 90: 2312-2316, 2004.
12. Balkwill F: Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 13: 135-141, 2002.
13. Szlosarek PW and Balkwill FR: Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol 4: 565-573, 2003.
14. Ayre JE: Cervical cancer: chronic inflammation, stress and adaptation factors. Acta Unio Int Contra Cancrum 12: 20-27, 1956.
15. Dalgleish AG and O'Byrne KJ: Chronic immune activation and inflammation in the pathogenesis of AIDS and cancer. Adv Cancer Res 84: 231-276, 2002.
16. Farrow B and Evers BM: Inflammation and the development of pancreatic cancer. Surg Oncol 10: 153-169, 2002.
17. Nelson WG, De Marzo AM, DeWeese TL and Isaacs WB: The role of inflammation in the pathogenesis of prostate cancer. J Urol 172: S6-S12, 2004.
18. Schwartsburd PM: Chronic inflammation as inductor of pro-cancer microenvironment: pathogenesis of dysregulated feedback control. Cancer Metastasis Rev 22: 95-102, 2003.
19. Tiwari N, Gheldof A, Tatari M and Christofori G: EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol 22: 194-207, 2012.
20. Chen MC, Chang WW, Kuan YD, Lin ST, Hsu HC and Lee CH: Resveratrol inhibits LPS-induced epithelial-mesenchymal transition in mouse melanoma model. Innate Immun 18: 685-693, 2012.
21. Lu JN, Lee WS, Kim MJ, Yun JW, Jung JH, Yi SM, Jeong JH, Kim HJ, Choi YH, Kim GS, et al: The inhibitory effect of anthocyanins on Akt on invasion and epithelial-mesenchymal transition is not associated with the anti-EGFR effect of the anthocyanins. Int J Oncol 44: 1756-1766, 2014.
22. Yang CS and Wang X: Green tea and cancer prevention. Nutr Cancer 62: 931-937, 2010.
23. Gloria NF, Soares N, Brand C, Oliveira FL, Borojevic R and Teodoro AJ: Lycopene and beta-carotene induce cell-cycle arrest and apoptosis in human breast cancer cell lines. Anticancer Res 34: 1377-1386, 2014.
24. Akl MR, Ayoub NM, Abuasal BS, Kaddoumi A and Sylvester PW: Sesamin synergistically potentiates the anticancer effects of γ-tocotrienol in mammary cancer cell lines. Fitoterapia 84: 347-359, 2013.
25. Tanabe H, Kuribayashi K, Tsuji N, Tanaka M, Kobayashi D and Watanabe N: Sesamin induces autophagy in colon cancer cells by reducing tyrosine phosphorylation of EphA1 and EphB2. Int J Oncol 39: 33-40, 2011.
26. Yokota T, Matsuzaki Y, Koyama M, Hitomi T, Kawanaka M, Enoki-Konishi M, Okuyama Y, Takayasu J, Nishino H, Nishikawa A, et al: Sesamin, a lignan of sesame, down-regulates cyclin D1 protein expression in human tumor cells. Cancer Sci 98: 1447-1453, 2007.
27. Deng P, Wang C, Chen L, Wang C, Du Y, Yan X, Chen M, Yang G and He G: Sesamin induces cell cycle arrest and apoptosis through the inhibition of signal transducer and activator of transcription 3 signalling in human hepatocellular carcinoma cell line HepG2. Biol Pharm Bull 36: 1540-1548, 2013.
28. Wang HM, Cheng KC, Lin CJ, Hsu SW, Fang WC, Hsu TF, Chiu CC, Chang HW, Hsu CH and Lee AY: Obtusilactone A and (-)-sesamin induce apoptosis in human lung cancer cells by inhibiting mitochondrial Lon protease and activating DNA damage checkpoints. Cancer Sci 101: 2612-2620, 2010.
29. Harikumar KB, Sung B, Tharakan ST, Pandey MK, Joy B, Guha S, Krishnan S and Aggarwal BB: Sesamin manifests chemopreventive effects through the suppression of NF-kappa B-regulated cell survival, proliferation, invasion, and angiogenic gene products. Mol Cancer Res 8: 751-761, 2010.
30. Liu L, Ge D, Ma L, Mei J, Liu S, Zhang Q, Ren F, Liao H, Pu Q, Wang T, et al: Interleukin-17 and prostaglandin E2 are involved in formation of an M2 macrophage-dominant microenvironment in lung cancer. J Thorac Oncol 7: 1091-1100, 2012.
31. Bieniek J, Childress C, Swatski MD and Yang W: COX-2 inhibitors arrest prostate cancer cell cycle progression by down-regulation of kinetochore/centromere proteins. Prostate 74: 999-1011, 2014.
32. Wang L, Zhu R, Huang Z, Li H and Zhu H: Lipopolysaccharide-induced toll-like receptor 4 signaling in cancer cells promotes cell survival and proliferation in hepatocellular carcinoma. Dig Dis Sci 58: 2223-2236, 2013.
33. Li Y, Fan L, Sun Y, Zhang D, Yue Z, Niu Y, Meng J, Yang T, Liu W and Mei Q: An apple oligogalactan suppresses endotoxin-induced cyclooxygenase-2 expression by inhibition of LPS pathways. Int J Biol Macromol 61: 75-81, 2013.
34. Lee CC, Liu KJ, Wu YC, Lin SJ, Chang CC and Huang TS: Sesamin inhibits macrophage-induced vascular endothelial growth factor and matrix metalloproteinase-9 expression and proangiogenic activity in breast cancer cells. Inflammation 34: 209-221, 2011.
35. Lu T and Stark GR: Cytokine overexpression and constitutive NFkappaB in cancer. Cell Cycle 3: 1114-1117, 2004.
36. Rousseau MC, Hsu RY, Spicer JD, McDonald B, Chan CH, Perera RM, Giannias B, Chow SC, Rousseau S, Law S, et al: Lipopolysaccharide-induced toll-like receptor 4 signaling enhances the migratory ability of human esophageal cancer cells in a selectin-dependent manner. Surgery 154: 69-77, 2013.
37. Zhang Y, Guo Z, Du T, Chen J, Wang W, Xu K, Lin T and Huang H: Prostate specific membrane antigen (PSMA): a novel modulator of p38 for proliferation, migration, and survival in prostate cancer cells. Prostate 73: 835-841, 2013.
38. Leelahavanichkul K, Amornphimoltham P, Molinolo AA, Basile JR, Koontongkaew S and Gutkind JS: A role for p38 MAPK in head and neck cancer cell growth and tumor-induced angiogenesis and lymphangiogenesis. Mol Oncol 8: 105-118, 2014.
39. Sukhtankar D, Okun A, Chandramouli A, Nelson MA, Vanderah TW, Cress AE, Porreca F and King T: Inhibition of p38-MAPK signaling pathway attenuates breast cancer induced bone pain and disease progression in a murine model of cancer-induced bone pain. Mol Pain 7: 81, 2011.